Recruiting studies: Well Differentiated Neuroendocrine Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

CompArative Analysis Between, Thymic, pulmonaRy and Pancreatic Well Differentiated High Grade Neuroendocrine Tumors
Phase N/A · 1 location(s) · European Institute of Oncology · NCT07429851 Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and
Phase 2 · 1 location(s) · Gustave Roussy, Cancer Campus, Grand Paris · NCT07016230 Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
Phase 1 · 20 location(s) · SystImmune Inc. · NCT07080242 Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
Phase 1 · 9 location(s) · RayzeBio, Inc. · NCT07165132 Surufatinib Combined With Chemo Versus Surufatinib in the Treatment of Pulmonary Neuroendocrine Tumors
Phase 2 · 4 location(s) · Shanghai Chest Hospital · NCT07357623 Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic P
Phase 3 · 40 location(s) · Intergroupe Francophone de Cancerologie Thoracique · NCT06937905 Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)
Phase N/A · 1 location(s) · University of Roma La Sapienza · NCT04464122 Pancreatic Radiofrequency Under High Echo-endoscopy in the Management of Pancreatic Neuroendocrine Tumors
NA · 1 location(s) · Institut Paoli-Calmettes · NCT04520932 Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with Long-acting Somatostatin Analogues - ATSA Trial
Phase 2/Phase 3 · 1 location(s) · The Netherlands Cancer Institute · NCT06855095 SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Dif
Phase 1 · 1 location(s) · Peter Hosein, MD · NCT06889493 A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced So
Phase 1 · 83 location(s) · Pfizer · NCT05538130 177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry
Phase 2 · 1 location(s) · University of Iowa · NCT06395402 Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown
Phase 2 · 6 location(s) · Centre Hospitalier Universitaire Dijon · NCT04325425 Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors
Phase 2 · 2 location(s) · AC Camargo Cancer Center · NCT06472388 Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 17
Phase 3 · 54 location(s) · RayzeBio, Inc. · NCT05477576 Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
Phase 3 · 51 location(s) · Crinetics Pharmaceuticals Inc. · NCT07087054 Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors
Phase N/A · 2 location(s) · University of Southern California · NCT07259304 Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors
Phase 2 · 1 location(s) · University of California, San Francisco · NCT05746208

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.